Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study
Q Gong, E W Gregg, J Wang, Y An, P Zhang, W Yang, H Li, H Li, Y Jiang, Y Shuai, B Zhang, J Zhang, R B Gerzoff, G Roglic, Y Hu, G Li, P H Bennett, Q Gong, E W Gregg, J Wang, Y An, P Zhang, W Yang, H Li, H Li, Y Jiang, Y Shuai, B Zhang, J Zhang, R B Gerzoff, G Roglic, Y Hu, G Li, P H Bennett
Abstract
Aims/hypothesis: We determined the effects of 6 years of lifestyle intervention in persons with impaired glucose tolerance (IGT) on the development of retinopathy, nephropathy and neuropathy over a 20 year period.
Methods: In 1986, 577 adults with IGT from 33 clinics in Da Qing, China were randomly assigned by clinic to a control group or one of three lifestyle intervention groups (diet, exercise, and diet plus exercise). Active intervention was carried out from 1986 to 1992. In 2006 we conducted a 20 year follow-up study of the original participants to compare the incidence of microvascular complications in the combined intervention group vs the control group.
Results: Follow-up information was obtained on 542 (94%) of the 577 original participants. The cumulative incidence of severe retinopathy was 9.2% in the combined intervention group and 16.2% in the control group (p = 0.03, log-rank test). After adjusting for clinic and age, the incidence of severe retinopathy was 47% lower in the intervention group than the control group (hazard rate ratio 0.53, 95% CI 0.29-0.99, p = 0.048). No significant differences were found in the incidence of severe nephropathy (hazard rate ratio 1.05, 95% CI 0.16-7.05, intervention vs control, p = 0.96) or in the prevalence of neuropathy (8.6% vs 9.1%, p = 0.89) among the 20 year survivors.
Conclusions/interpretation: Lifestyle intervention for 6 years in IGT was associated with a 47% reduction in the incidence of severe, vision-threatening retinopathy over a 20 year interval, primarily due to the reduced incidence of diabetes in the intervention group. However, similar benefits were not seen for nephropathy or neuropathy.
References
- Ophthalmology. 1991 May;98(5 Suppl):786-806
- Diabetologia. 2001 Sep;44 Suppl 2:S82-6
- Acta Diabetol. 1991;28(2):169-73
- Lancet. 2006 Sep 23;368(9541):1096-105
- Diabetologia. 2001 Sep;44 Suppl 2:S14-21
- Kidney Int. 1989 Feb;35(2):681-7
- Circulation. 2009 Apr 7;119(13):1728-35
- N Engl J Med. 2001 May 3;344(18):1343-50
- Arch Ophthalmol. 2004 Apr;122(4):552-63
- Diabetes Res Clin Pract. 2008 Nov 13;82 Suppl 1:S10-4
- Lancet. 2008 May 24;371(9626):1783-9
- Ann Intern Med. 2007 Aug 7;147(3):149-55
- World Health Organ Tech Rep Ser. 1985;727:1-113
- BMJ. 1999 Dec 4;319(7223):1492-5
- Lancet. 2009 Nov 14;374(9702):1677-86
- Diabet Med. 2007 Feb;24(2):137-44
- Diabetologia. 2006 Feb;49(2):289-97
- Arch Ophthalmol. 1984 Apr;102(4):520-6
- Diabetes Care. 2004 Jun;27(6):1458-86
- Arch Ophthalmol. 1984 Apr;102(4):527-32
- Kidney Int. 2005 Sep;68(3):1267-74
- Diabetes Care. 1997 Apr;20(4):537-44
- Diabetes Care. 2004 Jul;27(7):1591-7
- Diabetes Res Clin Pract. 2005 Feb;67(2):152-62
- N Engl J Med. 2002 Feb 7;346(6):393-403
- Diabetologia. 1988 Oct;31(10):730-6
Source: PubMed